GeoVax Labs (NASDAQ:GOVX) Releases Quarterly Earnings Results, Beats Estimates By $1.19 EPS

GeoVax Labs (NASDAQ:GOVX) announced its quarterly earnings data on Monday. The company reported ($0.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.16) by $1.19, FiscalAI reports.

GeoVax Labs Stock Up 3.9%

Shares of GOVX traded up $0.03 during trading hours on Monday, hitting $0.76. The company had a trading volume of 166,250 shares, compared to its average volume of 2,345,560. The firm has a market cap of $2.64 million, a P/E ratio of -0.04 and a beta of 3.68. The stock’s 50 day moving average price is $1.55 and its 200 day moving average price is $1.84. GeoVax Labs has a 52-week low of $0.69 and a 52-week high of $20.62.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on GOVX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GeoVax Labs in a research note on Friday, July 17th. D. Boral Capital reissued a “hold” rating on shares of GeoVax Labs in a research note on Thursday, April 16th. Finally, Wall Street Zen raised shares of GeoVax Labs from a “sell” rating to a “hold” rating in a research note on Sunday, June 21st. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $150.00.

Institutional Investors Weigh In On GeoVax Labs

Several institutional investors have recently bought and sold shares of GOVX. Jane Street Group LLC bought a new position in GeoVax Labs during the 4th quarter worth approximately $99,000. HRT Financial LP purchased a new position in GeoVax Labs in the 4th quarter worth approximately $31,000. Renaissance Technologies LLC bought a new stake in GeoVax Labs in the fourth quarter valued at approximately $104,000. Finally, Armistice Capital LLC bought a new stake in GeoVax Labs in the third quarter valued at approximately $253,000. 6.09% of the stock is currently owned by hedge funds and other institutional investors.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.